Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. (Q30366836)

21 June 2017

title

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. (English)

1 reference

21 June 2017

1 reference

1 reference

1 reference

1

Andreas Wack

1 reference

21 June 2017

11

Emanuele Montomoli

1 reference

21 June 2017

13

Rino Rappuoli

1 reference

21 June 2017

5

Sandra Nuti

1 reference

21 June 2017

Barbara C Baudner

2

1 reference

21 June 2017

Anne K Hilbert

3

1 reference

21 June 2017

Ilaria Manini

4

1 reference

21 June 2017

Simona Tavarini

6

1 reference

21 June 2017

Hanno Scheffczik

7

1 reference

21 June 2017

Mildred Ugozzoli

8

1 reference

21 June 2017

Manmohan Singh

9

1 reference

21 June 2017

Jina Kazzaz

10

1 reference

21 June 2017

Giuseppe Del Giudice

12

1 reference

21 June 2017

Derek T O'Hagan

14

1 reference

21 June 2017

language of work or name

English

0 references

publication date

7 December 2007

1 reference

21 June 2017

1 reference

21 June 2017

volume

26

1 reference

21 June 2017

issue

4

1 reference

21 June 2017

page(s)

552-561

1 reference

Mortality associated with influenza and respiratory syncytial virus in the United States

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Avian influenza A (H5N1) infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Serious morbidity and mortality associated with influenza epidemics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Antibody response to influenza vaccination in the elderly: a quantitative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Influenza A virus specific T cell immunity in humans during aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Cytokine production after influenza vaccination in a healthy elderly population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Cytokines and impaired CD8+ CTL activity among elderly persons and the enhancing effect of IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4+ T cells in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

The unmet need in the elderly: designing new influenza vaccines for older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Use of CpG oligodeoxynucleotides as immune adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Epitopes involved in antibody-mediated protection from Ebola virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Direct access to CD4+ T cells specific for defined antigens according to CD154 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Lymphoproliferative Responses to Recombinant HIV‐1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

CD4 T cell responses to influenza infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.11.054

10.1016/J.VACCINE.2007.11.054

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference